Survodutide
- •what is Survodutide
- •Survodutide vs Tirzepatide
- •Survodutide BI 456906
- •Survodutide weight loss
- •Survodutide GLP-1 glucagon
- Survodutide(GLP-1/Glucagon dual agonist)· Weight Loss & Metabolism
- Survodutide is one of the most-watched investigational weight-loss peptides. Like Mazdutide, it goes a step beyond semaglutide by activating both GLP-1 and glucagon receptors — reducing appetite while simultaneously raising metabolic rate. Phase 2 trials produced weight-loss numbers in the same ballpark as tirzepatide, and the program is now in late-stage development for obesity and NASH (fatty liver disease).
What is it?
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist in late-stage clinical development by Boehringer Ingelheim and Zealand Pharma. Like mazdutide, it combines GLP-1's appetite-reducing effects with glucagon's energy-expenditure-boosting effects. It has shown impressive weight-loss results in phase 2 trials and is positioned as a competitor in the next-generation obesity drug landscape. Research-grade material is sold strictly for laboratory use.
In plain English
Survodutide is one of the most-watched investigational weight-loss peptides. Like Mazdutide, it goes a step beyond semaglutide by activating both GLP-1 and glucagon receptors — reducing appetite while simultaneously raising metabolic rate. Phase 2 trials produced weight-loss numbers in the same ballpark as tirzepatide, and the program is now in late-stage development for obesity and NASH (fatty liver disease).
How it works
Survodutide is a balanced dual agonist of the GLP-1 and glucagon receptors. The GLP-1 component reduces appetite, slows gastric emptying, and supports insulin secretion. The glucagon component increases hepatic energy expenditure and supports lipid metabolism. The molecule is designed for once-weekly subcutaneous dosing.
What researchers study
- •Obesity and chronic weight management
- •Non-alcoholic steatohepatitis (NASH)
- •Type 2 diabetes
- •Cardiometabolic outcomes
- •Dual-agonist pharmacology
What the internet talks about
Survodutide is a frequent topic in weight-loss and biohacker forums tracking next-generation GLP-1 drugs. Discussion centers on its phase 2 weight loss (~19% over 46 weeks in some cohorts), its NASH results, and how it stacks up against tirzepatide, retatrutide, and mazdutide.
Bro-science translation
“Dual-action GLP-1 + glucagon weight-loss heavyweight in the making.”
Commonly compared to
Common stack discussions
Typically monotherapy in trials. Forum users compare it to tirzepatide and retatrutide rather than stacking with them.
Related peptides
Related categories
Frequently asked questions
Quick summary
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist in late-stage trials for obesity and NASH. Phase 2 weight loss results rival tirzepatide. Sold for laboratory research only.